<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156362</url>
  </required_header>
  <id_info>
    <org_study_id>2011.665</org_study_id>
    <nct_id>NCT02156362</nct_id>
  </id_info>
  <brief_title>Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)</brief_title>
  <official_title>Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is generally estimated that 5 % of patients with thyroid cancer will develop distant
      metastases, and most of them had an advanced stage of the disease at presentation. Thirty per
      cent of them are resistant to radio iodine therapy and are called &quot;refractory&quot;. Their long
      term survival is estimated to be less than 10 %.

      The objective of this study is to identify the factors associated with poor outcome in a
      cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and
      medullary thyroid carcinomas were excluded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Thyroid cancer evolving to refractory stage</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>follow up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>follow up visit</intervention_name>
    <description>At least 1 follow up visit per year will be done and an additional visit if needed.</description>
    <arm_group_label>follow up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman ≥ 18 years.

          -  Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly
             differentiated carcinoma).

          -  TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.

          -  Patient after post operative radioiodine therapy.

        Exclusion Criteria:

          -  Patient who can not be followed during the protocol.

          -  Patient who does not consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire BOURNAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon- Centre de Médecine Nucléaire Groupement hospitalier est, 59 boulevard Pinel, 69677 Bron cedex</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire BOURNAUD, MD</last_name>
    <phone>+33472356999</phone>
    <email>claire.bournaud-salinas@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Françoise BORSON-CHAZOT, PHD,MD</last_name>
    <phone>+33472119319</phone>
    <email>francoise.borson-chazot@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel</name>
      <address>
        <city>Bron cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire BOURNAUD, MD</last_name>
      <phone>+33472356999</phone>
      <email>claire.bournaud-salinas@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Françoise BORSON-CHAZOT, PHD,MD</last_name>
      <phone>+33472119319</phone>
      <email>francoise.borson-chazot@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Claire BOURNAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thyroid carcinoma</keyword>
  <keyword>predictive factors</keyword>
  <keyword>refractory</keyword>
  <keyword>Differentiated</keyword>
  <keyword>follicular origin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

